Professor and Chairman
Department of Urology
Dr. Robert S. Svatek completed Urology residency at the University of Texas Southwestern Medical Center at Dallas from July 2002 June 2007. Dr. Svatek continued his Clinical Fellowship and Research in Urologic Oncology at University of Texas MD Anderson Cancer Center from July 2007 to June 2010 at the same time earned his Master of Science (MS) in Clinical Research Investigation at the University of Texas Health Science Center at Houston, Center for Clinical Research and Evidence-Based Medicine. Dr. Svatek joined UT Health San Antonio in 2010.
MSCI, UT Health San Antonio (2009)
M.D., University of Texas Medical Branch Galveston (2002)
University of Texas MD Anderson Cancer Center, Fellowship, Urologic Oncology (2010)
University of Texas Southwestern Medical Center, Residency, Urology (2007)
University of Texas Southwestern Medical Center, Internship, General Surgery (2003)
Dr. Svatek’s expertise is in the evaluation and management of urologic cancers, with a primary focus on patients with bladder cancer. He performs both robotic and open surgery for bladder cancer. He utilizes a comprehensive care plan for patients with bladder cancer that sometimes requires coordination with medical oncologists, radiation oncologists, or both. Dr. Svatek performs surgery at the UT Medicine Ambulatory Surgery Center, University Hospital, Christus Santa Rosa Northwest Hospital, and the Audie L. Murphy Memorial Veterans Hospital. Dr. Svatek sees patients in clinic at the UT Medicine Medical Arts and Research Center.
The major area of interest is in identifying and testing novel therapies for patients with bladder cancer. In addition, he is interested in improving the quality of surgical care for patients undergoing major surgery for invasive bladder cancer.
1: Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM Jr. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 May 8;319(18):1880-1888. doi: 10.1001/jama.2018.4657. PMID: 29801011; PMCID: PMC6583489.
2: Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA Jr, Thompson IM. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 Jun 23;391(10139):2525-2536. doi: 10.1016/S0140-6736(18)30996-6. PMID: 29976469.
3: Svatek RS. Editorial Comment. J Urol. 2018 Jun;199(6):1451. doi: 10.1016/j.juro.2017.12.077. Epub 2018 Mar 12. PMID: 29545192.
4: Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11. PMID: 31712383.
5: Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle- Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. Erratum in: J Clin Oncol. 2019 Aug 20;37(24):2187. PMID: 28834453; PMCID: PMC5648171.
6: Zhang S, Chang W, Wu H, Wang YH, Gong YW, Zhao YL, Liu SH, Wang HZ, Svatek RS, Rodriguez R, Wang ZP. Pan-cancer analysis of iron metabolic landscape across the Cancer Genome Atlas. J Cell Physiol. 2020 Feb;235(2):1013-1024. doi: 10.1002/jcp.29017. Epub 2019 Jun 25. PMID: 31240715.
7: Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA Jr, Thompson IM, Parekh DJ. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 Mar;203(3):522-529. doi: 10.1097/JU.0000000000000565. Epub 2019 Sep 24. PMID: 31549935; PMCID: PMC7487279.
8: Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10. PMID: 30968729; PMCID: PMC6595543.
9: Lerner SP, Svatek RS. What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy? Eur Urol. 2019 Apr;75(4):612-614. doi: 10.1016/j.eururo.2018.12.028. Epub 2019 Jan 4. PMID: 30616946.
10: Mukherjee N, Svatek RS, Mansour AM. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer. Urol Oncol. 2018 Mar;36(3):103-108. doi: 10.1016/j.urolonc.2017.12.020. Epub 2018 Feb 9. PMID: 29429897; PMCID: PMC6428193.